SPY423.47-0.85 -0.20%
DIA343.00-2.12 -0.61%
IXIC14,113.90+44.48 0.32%

Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $53

Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $55 to $53.

05/10/2021 07:34
Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $55 to $53.